The Filing Desk

Prothena

PRTA · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

PRTA · Last close · November 19, 2026
$8.40
Value Prothena yourself

Prothena's revenue fell 92.8% to $10 million in fiscal 2025. Its operating margin was −2,216.4%, down from −114.4% a year earlier. The diluted share count rose 0.1%.

PROTHENA CORPORATION PUBLIC LIMITED COMPANY Latest fiscal year ended December 31, 2025 10-K filed February 27, 2026 · 0001559053-26-000008 Updated
Revenue
$10M
92.8%
Operating margin
−2,216.4%
2102.1 pts
Net income
−$244M
 
Free cash flow
—
 
Return on equity
−63.6%
40.3 pts
Market cap
$432M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Prothena does

Prothena is a clinical-stage biotechnology company based in Ireland. It develops treatments for diseases caused by misfolded proteins, including Parkinson's disease, Alzheimer's disease, ATTR amyloidosis with cardiomyopathy (a rare, fatal disease in which misfolded proteins build up in the heart) and ALS. It has no approved products.

Its active clinical programs are all partnered with large drug companies. Prasinezumab is in a Phase 3 trial for early Parkinson's disease with Roche. Coramitug is in a Phase 3 trial for ATTR cardiomyopathy run by Novo Nordisk. BMS-986446 is in a Phase 2 trial for early Alzheimer's disease run by Bristol Myers Squibb, and PRX019 is in a Phase 1 trial run by Prothena as part of a partnership with Bristol Myers Squibb.

Its early-stage research includes a technology called CYTOPE, meant to reach disease targets inside cells, and preclinical work on PRX012, a wholly-owned antibody for Alzheimer's disease. It says it is looking for research collaborations and licensing deals with large drug companies. As of December 31, 2025, it had 67 employees, 36 of them in research and development.

Its biggest risks, as it describes them

  • It expects to keep losing money and may never sustain profitability.
  • It needs more capital, and may not be able to raise it.
  • It depends on partners such as BMS, Roche and Novo Nordisk to carry its drug candidates forward.
  • Clinical trials may be delayed or fail, and regulators may not approve its drug candidates.
  • It must keep and attract key staff, and partners may want assurance of its stand-alone financial strength.
From Prothena's annual report on Form 10-K, filed February 27, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Prothena lost money in fiscal 2025: a net loss of $244 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments579710619471308
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio17.5x14.3x11.2x10.0x7.7x
Quick ratio17.5x14.3x11.2x10.0x7.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Free cash flow is cash from operations minus capital expenditure. The SEC's structured data for Prothena's filings doesn't give both for any year, so free cash flow is left out.

Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Prothena's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Prothena says to expect

  • Full year 2026: cash used and year-end cashThe Company continues to expect its full year 2026 net cash used in operating and investing activities to be $18 to $23 million and to end the year with approximat ely $259 million (midpoint) in cash, cash equivalents and restricted cash.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 5, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $7.7 million of Prothena shares on the open market, and 2 insiders sold $135,926, all of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 17, 2026William P Scully10% ownerBought50,000$8.09$404,680Form 4
Sep 29, 2026William P Scully10% ownerBought162,000$8.68$1.4 millionForm 4
Sep 28, 2026William P Scully10% ownerBought103,500$8.60$890,100Form 4
Sep 18, 2026William P Scully10% ownerBought100,000$8.43$843,000Form 4
Sep 2, 2026William P Scully10% ownerBought27,000$9.47$255,690Form 4
Aug 20, 2026William P Scully10% ownerBought50,000$8.79$439,500Form 4
Aug 7, 2026William P Scully10% ownerBought37,500$8.62$323,250Form 4
Jul 29, 2026Michael John IsaacsGeneral Counsel & Company Sec.Sold plan8,386$8.47$71,029Form 4
Jul 29, 2026Anne Evans KingstonChief Strategy OfficerSold plan7,662$8.47$64,897Form 4
Jun 16, 2026William P Scully10% ownerBought20,000$7.90$158,000Form 4
Jun 11, 2026William P Scully10% ownerBought125,000$8.17$1.0 millionForm 4
Jun 4, 2026William P Scully10% ownerBought50,000$9.31$465,500Form 4
The latest 12 of 14 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40———
Altman Z''3.425.27−5.98
Accruals ratio−1.8%4.5%−18.4%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassFail
Cash from operations exceeds net incomePassFailPass
Debt fell relative to assets———
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassPassFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Prothena side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
ProthenaFY25−92.8%−2,216.4%————
Taysha Gene TherapiesFY2517.3%−1,130.7%−960.1%——4Compare
Janux TherapeuticsFY25−5.5%−1,576.7%−832.8%———Compare
CurisFY25−13.4%−60.5%———3Compare
Alpha CognitionFY25—−221.7%−202.3%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue128111201549113510
Revenue growth−34.4%2,508.4%−96.5%−14.8%4.8%23,414.3%−73.1%69.5%47.9%−92.8%
Gross profit——————————
Research and development120134101517582136221222135
Operating income−160−155−159−86−11372−132−191−155−215
Net income−160−153−156−78−11167−117−147−122−244
Diluted EPS (US$)−4.66−4.07−3.93−1.95−2.781.38−2.47−2.76−2.27−4.53
Diluted shares (millions)34384040404847535454
Cash flow
Cash from operations−116−131−28−53−8093−109−134−150−164
Capital expenditure——————————
Free cash flow——————————
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation25272724222531414638
Balance sheet at fiscal year end
Cash and short-term investments387418428376295579710619471308
Debt incl. finance leases——————————
Total assets460496499419333609758696547327
Total liabilities95891761461491431361356046
Shareholders' equity365407323273184466622561487280
Margins and ratios
Gross margin——————————
Operating margin−15,121.8%−564.2%−16,634.0%−10,527.9%−13,216.2%35.9%−244.1%−209.1%−114.4%−2,216.4%
Net margin−15,176.1%−556.8%−16,297.9%−9,542.6%−13,029.8%33.4%−216.9%−160.9%−90.5%−2,520.6%
Free cash flow margin——————————
Rule of 40 (growth + FCF margin)——————————
Return on capital——————————
Return on equity−44.1%−39.7%−42.6%−26.1%−48.6%20.6%−21.5%−24.9%−23.3%−63.6%
Return on assets−37.9%−32.0%−31.3%−16.9%−29.6%14.2%−17.1%−20.2%−19.7%−55.9%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Prothena's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Prothena.